{
  "id": 19390970,
  "title": "Celcuity at guggenheim healthcare innovation conference: launch gains pace",
  "url": "https://urgent.news/2026/11/10/celcuity-at-guggenheim-healthcare-innovation-conference-launch-gains",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-10T20:35:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/celcuity-at-guggenheim-healthcare-innovation-conference-launch-gains-pace-93CH-5016714"
  },
  "original_language": "en",
  "account": null,
  "summary": "Celcuity, a precision oncology company, recently launched its cancer drug REVTORPYK at the Guggenheim Healthcare Innovation Conference. The drug, approved for patients with second-line HR-positive, HER2-negative advanced breast cancer, is gaining early traction and is being ordered by 80% of strategic accounts about six weeks after its launch. Celcuity's newly launched cancer drug REVTORPYK is gaining early traction, even as the company works through reimbursement, manufacturing and international expansion issues. The precision oncology company also pointed to a broader pipeline in breast and prostate cancer that it says could support much larger revenue over time.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}